Immunoactivative role of indoleamine 2,3-dioxygenase in gastric cancer cells in vitro

Molecular Medicine Reports

Volumn 4, Issue 1, 2011, Pages 169-173

  Zhang, Rupeng ^a   Li, Hui ^a   Yu, Jinpu ^a   Zhao, Jingzhu ^a   Wang, Xuejun ^a   Wang, Gang ^a   Yao, Zhoujia ^a   Wei, Feng ^a   Xue, Qiang ^a   Ren, Xiubao ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

3 dioxygenase; Gastric cancer; Indoleamine 2; T cell cytotoxicity; T cell proliferation; Tumor escape

Indexed keywords

1 METHYLTRYPTOPHAN; AMINO ACID; ENHANCED GREEN FLUORESCENT PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; KYNURENINE; TRYPTOPHAN; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; ENZYME ACTIVITY; GENE INSERTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MOLECULAR CLONING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; T LYMPHOCYTE; TUMOR IMMUNITY;

CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CLONING, MOLECULAR; ELECTROPORATION; GENE TRANSFER TECHNIQUES; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; RNA, MESSENGER; STOMACH NEOPLASMS; T-LYMPHOCYTES;

EID: 78651381598     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2010.398     Document Type: Article

References (10)

1. Munn DH and Mellor AL: Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117: 1147-1154, 2007.
2. Fallarino F, Grohmann U, You S, et al: The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176: 6752-6761, 2006. (Pubitemid 43787857)
3. Hou W, Li S, Wu Y, Du X and Yuan F: Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates crescentic glomerulonephritis. Clin Exp Immunol 156: 363-372, 2009.
4. Uyttenhove C, Pilotte L, Théate I, et al: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9: 1253-1254, 2003. (Pubitemid 37279849)
5. - T-cells in cytokine-induced killers might favor the antitumor cytotoxicity of cytokine-induced killers in vivo. Cancer Biother Radiopharm 21: 276-284, 2006. (Pubitemid 44115198)
6. Gajewski TF, Meng Y and Harlin H: Immune suppression in the tumor microenvironment. J Immunother 29: 233-240, 2006.
7. Fallarino F, Grohmann U, Vacca C, et al: T cell apoptosis by tryptophan catabolism. Cell Death Differ 9: 1069-1077, 2002.
8. Belladonna ML, Grohmann U, Guidetti P, et al: Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol 177: 130-137, 2006. (Pubitemid 43939124)
9. Forouhar F, Anderson JL, Mowat CG, et al: Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase. Proc Natl Acad Sci USA 104: 473-478, 2007.
10. Hou DY, Muller AJ, Sharma MD, et al: Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67: 792-801, 2007